Replimune Group, Inc.
REPL Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$13.05
KIRA · Stoqly’s AI analyst, in plain words
- Replimune Group, Inc. lost $314M in fiscal 2026.
- Free cash flow was −$285M in fiscal 2026, — of revenue.
- Replimune Group, Inc. has $161M more cash than debt.
Market cap
$1.3B
P/E
—
Revenue
—
Net income
−$314M
Free cash flow
−$285M
Operating margin
—
Replimune Group, Inc. in 30 seconds · fiscal 2026
Does it make a profit?
−$314M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Replimune Group, Inc. does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · Jun 29, 2026
- Legal name
- Replimune Group, Inc.
- CIK
- 0001737953
Replimune Group, Inc. · REPL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$118M | −$174M | −$216M | −$247M | −$314M |
| Diluted EPS | −$2.26 | −$2.99 | −$3.24 | −$3.07 | −$3.38 |
| Cash | |||||
| Cash from operations | −$82.2M | −$128M | −$185M | −$192M | −$280M |
| Capital expenditure | $2.3M | $2.3M | $5.7M | $6.7M | $4.2M |
| Free cash flow | −$84.5M | −$130M | −$191M | −$199M | −$285M |
| Share count change | 12.9% | 11.5% | 14.4% | 21.0% | 15.2% |
| Debt and strength | |||||
| Cash and short-term investments | $396M | $583M | $421M | $484M | $269M |
| Debt incl. finance leases | $27.0M | $55.3M | $70.9M | $71.9M | $108M |
| Shareholders' equity | $411M | $555M | $375M | $416M | $166M |
| Current ratio | 19.5x | 17.5x | 10.7x | 8.0x | 4.8x |
| Interest coverage | — | −90.2x | −52.2x | −45.3x | −47.1x |
| Returns and quality | |||||
| Return on capital | −600.2% | −25,251.5% | — | — | — |
| Return on equity | −25.9% | −36.1% | −46.4% | −62.6% | −107.9% |
| Return on tangible equity | −28.7% | −31.4% | −57.6% | −59.5% | −188.9% |
| Piotroski F-score | — | 1 | 1 | 2 | 1 |
| Altman Z'' | 10.2 | 7.8 | 0.8 | −0.4 | −13.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.9M
7 insiders
Of sales under plans
14%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Replimune Group, Inc. · REPL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $13.05 a share, the company is worth $1.3B.
Source: SEC EDGAR XBRL filings (CIK 0001737953). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.